Pediatric Clinical Trials

April 25, 2017 | by City of Hope

City of Hope

Treating children, adolescents and young adults with cancer and blood diseases demands special attention. At City of Hope, we are honored to partner with you in determining the best treatment options for your younger patients. Our team of clinical specialists and researchers are pioneering innovative treatments for pediatric cancer and childhood diseases, including advances in gene therapy, immunotherapy and targeted therapy.

Refer your patient to one of our clinical trials and they will benefit from:
  • Program acceptance to anyone up to age 26.
  • Access to a large number of clinical trials, including all Children’s Oncology Group clinical trials and adult trials that are typically difficult for pediatricians to access.
  • Access to many phase 1 and phase 2 clinical trials — including immunotherapy, cell therapy and new agent trials — available only at City of Hope.
  • Our expertise in treating newly diagnosed patients and patients with relapsed or refractory leukemia. Our renowned stem cell transplantation program offers a quick and seamless transition to those patients needing hematopoietic stem cell transplants.
Referral is easy and we provide continuing communication between referring physicians and our team.
For a full listing of our clinical trials, please visit CityofHope.org/clinical-trials.
To refer a patient, please call 626-218-1133
or contact Dr. Sun directly (see information below).
My team looks forward to having the opportunity to collaborate with you. For immediate response, please contact me via phone or email.

Warm regards,

Weili Sun, M.D., Ph.D.
Director, Pediatric Leukemia Program

Email: [email protected]
Office: 626-218-8858
Cell: 626-383-2775
RELAPSED AND/OR REFRACTORY AML
IRB 13272: Phase 1 Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients with Relapsed or Refractory CD123+ Acute Myeloid Leukemia
Eligibility Criteria:
Rel/Refr ≥ 18yrs
CD123+
Very limited slots
IRB 13474: SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
Eligibility Criteria:
Rel/Refr (AML <20% blasts)
Age ≥ 18yrs
Prior ALLO >60 days
IRB 14269: A Phase 1/2 Trial of 8-Chloro-adenosine in Relapsed or Refractory Acute Myeloid Leukemia
Eligibility Criteria:
Rel/Refr ≥ 18yrs
Limited slots available
IRB 15123: A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Eligibility Criteria:
Rel/Refr ≥ 18yrs
Prior ALLO > 3 mos
Limited slots available
IRB 15367: Pilot study of Crenolanib Combined with High-dose Cytarabine and Mitoxantrone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Eligibility Criteria:
Age ≥ 18 yrs
FLT3-ITD / FLT3-D85
IRB 16203: A Phase 1 Study of SGN-CD123A in patients with relapsed or refractory Acute Myeloid Leukemia (AML)
Eligibility Criteria:
CD 123+
Limited slots
No prior transplant
RELAPSED AND/OR REFRACTORY ALL
IRB 13447: Phase 1 Study to Evaluate Cellular Immunotherapy Using Central Memory- Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients with High-Risk CD19+ Acute Lymphoblastic Leukemia
Eligibility Criteria:
CD19+; recurrent, PD or MRD following therapy
second CR or higher
Age ≥ 18yrs
IRB 16180: Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL / T-LBL Patients
Eligibility Criteria:
r/r T-ALL or T-LBL only
Age ≥ 15yrs
Prior Allo >60 days
                                                           

Categories : Clinical Trials

Back To Top

Search Blogs